Meeting
2014 ASCO Annual Meeting
The safety and tolerability of veliparib (V) plus capecitabine (C) and radiation (RT) in subjects with locally advanced rectal cancer (LARC): Results of a phase 1b study.
Authors
Brian G. Czito
Duke University Medical Center, Durham, NC
Brian G. Czito , Mary Frances Mulcahy , William R. Schelman , Houman Vaghefi , Gayle S. Jameson , Angela Deluca , Hao Xiong , Wijith Munasinghe , Matthew W. Dudley , Kyle D. Holen , Michael Michael
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT01589419
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 3634)
DOI
10.1200/jco.2014.32.15_suppl.3634
Abstract #
3634
Poster Bd #
97
Abstract Disclosures
Similar Posters
Poster
2015 Gastrointestinal Cancers Symposium
The safety and tolerability of veliparib (V) plus capecitabine (C) and radiation (RT) in subjects with locally advanced rectal cancer (LARC): Results of a phase 1b study.
First Author: Brian G. Czito
Poster
2015 ASCO Annual Meeting
Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer (LARC): Final results of a phase Ib study.
First Author: Michael Michael
Poster
2021 Gastrointestinal Cancers Symposium
A multicenter phase Ib/II study of DNA-PK inhibitor peposertib (M3814) in combination with capecitabine and radiotherapy in patients with locally advanced rectal cancer.
First Author: Paul Bernard Romesser
Poster
2020 ASCO Virtual Scientific Program
A multicenter phase Ib/II study of DNA-PK inhibitor peposertib (M3814) in combination with capecitabine and radiotherapy in patients with locally advanced rectal cancer.
First Author: Paul Bernard Romesser